Seeking Alpha

Roland Rick Perry's  Instablog

Roland Rick Perry
Send Message
Roland Rick Perry is the Managing Director of Institutional Analyst Inc. (IA), an independent investment research and investor relations firm, as well as editor of nine industry specific investment reviews. One of the best one mile runners to come out of the Chicago area, he attended Southern... More
My company:
Disclaimer
My blog:
Internet Stock Review
View Roland Rick Perry's Instablogs on:
  • Initiating Coverage On Innovus (INNV) $0.13.

    ==================================================

    Biotech & Stem Cell Stock Review, Tuesday, 03/17/2015.

    Los Angeles, CA 63 …84F Fair.

    Chicago, IL 40…73F Partly Cloudy.

    Delray Beach, FL 72…80 Partly Cloudy.

    Port Jefferson, NY 38…46F Fair. (198)

    ==================================================

    1. Initiating Coverage on Innovus (OTCQB:INNV) $0.13.

    2. HIV Vaccine Trial Launches in South Africa.

    3. Apricus Biosciences (NASDAQ:APRI) $1.86, Provides Corporate Update and 2014 Year-End Financial Results.

    4. Galena Biopharma (NASDAQ:GALE) $1.38, Announces Pricing of Public Offering of $38 Million.

    5. What Is A Stem Cell? California Institute for Regenerative Medicine

    6. Disclaimer.

    ==================================================

    To contact us send an email to: biotechstockreview@gmail.com

    ==================================================

    Top 5 Performers on the Biotech Watch List.

    Cellular Biomedicine (OTCQB:CBMG) up 139%

    Cellular Dynamics (NASDAQ:ICEL) up 68%

    Apricus (APRI) up 37%

    Bio-AMD (OTCQB:BIAD) up 25%

    Aethlon Medical (OTCQB:AEMD) up 19.4%

    2015 Watch List:

    biotechstockreview.ning.com/profiles/blo...

    Biotech Stock Review

    thebiotechstockreview.com/

    Biotech Stock Magazine

    goo.gl/Be85PZ

    Biotech & Stem Cell Exec TV

    www.biotechexectv.com/home.html

    =====

    Top 5 Performers on Stem Cell Watch List.

    Cellular Biomedicine (OTCQB:CBMG) up 139%

    American Cryostem (OTCPK:CRYO) up 124%

    Asterias Biotherapeutics, Inc. (OTC:AST) up 111%

    Cytori Therapeutics, Inc. (NASDAQ:CYTX) up 79%

    Cellular Dynamics (ICEL) up 68%

    2015 Watch List:

    biotechstockreview.ning.com/profiles/blo...

    Stem Cell Stock Review

    www.stemcellstockreview.com/

    Stem Cell Magazine

    goo.gl/OHBnWu

    Biotech Exec TV

    www.biotechexectv.com/

    And of course past performance provides no predictive algorithmic indication to future performance.

    ==================================================

    Initiating Coverage on Innovus ($INNV) $0.13.

    Innovus (OTCQB:INNV) is akin to a publicly traded "Shark Tank" without the cameras and we believe they just landed their biggest find to date. They specialize primarily in acquiring consumer goods products for the OTC healthcare market.

    We believe there is incredible potential here. Incredible in that no one appears to have noticed their recently announced acquisition of Novalere FP., Inc. and with it, acquiring the rights to Fluticare. Fluticare is a soon to launch nasal spray (using fluticasone propionate) which is active ingredient used in the well known Flonase, which went generic in 2006 - after first being launched in 1994. Acquiring a future competitor to Flonase using Flonase's own ingredient - is quite the coup.

    Also incredible, is that there are only 26 million shares outstanding, giving it a market cap of only around $4 million. When you add in the stock issued to acquire Novalere (25 million), the market cap is still under $8 million. We really don't think anyone saw the acquisition press release. We stumbled upon it quite by accident. How could any half-way "decent" start-up competitor to Flonase (using Flonase's own secret sauce) be valued so cheaply? Maybe because no one has heard of them?

    In our opinion given time, Fluticare will prove to be much more than just a decent competitor. We have spoke to management and they are driven. They want to see this work and they want to see this work big.

    While they may seem under-capitalized when going against billion marketing giants like Glaxo (which owns Flonase), this is United States and creme does rise to the top. The US is a market where you just can't keep a well marketed product down - regardless of the initial marketing budget.

    Nor can you keep down a aggressive and determined management team. There are many examples of where large multi-national corporations have made the mistake to look down at a small start-up competitor as a mere nuisance and shooed them off - and later gone on to regret it.

    From an "inherent" marketing standpoint (meaning packaging, positioning etc) we believe Innovus will shine with Fluticare in the years to come. It will become known as their centerpiece acquisition, which put them on the map.

    And as long as there are people suffering from allergies, there will be a demand for the active ingredient (by far the most popular and effective), that's a given. So the question is, can Fluticare make serious inroads into Flonase? Only time will tell. The question to ask is an $8 million market valuation low enough, to give you the benefit of the doubt and become a shareholder? We think so and we have.

    An estimated 50 million people in the United States have nasal allergies, often leading to fatigue, trouble sleeping, learning and attention problems, and performance trouble at work or school. Flonase sell for about $14 at Walmart. Yes, this is a very big market.

    SEC filing of Novalere FP acquisition: www.otcmarkets.com/edgar/GetFilingHtml?F...

    We assume Novalere agreed to be acquired by Innovus as a rapid and hassle free way to have their interests (now shares) publicly traded. As shareholders of 25 million shares, the better Fluticare sells, the better Innovus shares will fair. If the stock goes to $1.00 - Novalere's shares would be worth $25 million. They are incentivized. You can't do that on Shark Tank.

    Innovus at $0.13 is trading at its low of the year, down from high of near $1.00 back in 2013. It really is an unknown company with a very clever business plan and very capable and proven management.

    We came across the Innovus name when studying Apricus Biosciences (APRI) which is also on our Watch List and discovered that the CEO (from January of 2013) Bassam Damaj Ph.D, was formerly the President and CEO of Apricus and was responsible for the approval of its lead drug, Vitaros and also signed rather impressive multi-million-dollar partnerships between Apricus and leading pharmaceutical companies, such as Abbott, Novartis-Sandoz and Takeda. Like we said, capable.

    Apricus was trading around the equivalent of $7 and a market cap of near $100 million while he was at the helm. We are sure Novalere is aware of this too - and another reason they decided to be taken over by Innovus. In a recent interview on CEOLive, he stated he took Apricus from a $16 million market cap to $100 million. Management is not shy of their past accomplishments and as we stated earlier, want to see this work and work big. Expect to hear a lot about them, as the product rolls out.

    If Innovus succeeds with the launch and marketing of Fluticare like we think they will, there will be dozens of companies knocking on their door in hopes of being acquired. As a negotiator, to continue to draw on the Shark Tank analogy, Bassam Damaj is most like Mark Cuban - thoughtful and open only to natural fits.

    Back to Fluticare, most importantly, the FDA recently approved Flonase Allergy Relief for over-the-counter use in July of 2014. Meaning no more prescriptions needed. This is the second nasal steroid to be approved without a prescription in the past year. The first was Nasacort 24HR.

    So why are we excited about Fluticare? The company believes that with the price drop after going generic and the expanded availability now that it can be bought without a prescription, that the market could expand to 77 million units (per year) or over $1 billion in sales, retail. Remember, at $0.13, this newly arriving competitor has an $8 million market cap.

    Secondly, we've seen the proposed packaging for Fluticare (which we think is a better name than Flonase - it's just happier) and it looks just great. Certainly better than the Flonase packaging which looks like a big green thumb. Unfortunately we haven't been able to find a photo which we can share, probably due to regulatory requirements on the internet.

    We saw the packaging during an investor conference and it can be seen in the investor section of their website. Click on the link below and go to page 12-13. Keep in mind this is not for sale in the US yet, as they have a few regulatory hurdles (the ANDA filing) to jump though first.

    Innovus February 2015 Presentation:

    www.innovuspharma.com/pdf/Corporate-Pres...

    As you can see, the packaging looks great. As does the point of sale display. The "skinny tower" as they call it.

    The Flonase display in out opinion, is just downright weird:

    www.chaindrugreview.com/_assets/image/Fl...

    Here is the projected timeline for the launch of Fluticare. They must file an ANDA (Abbreviated New Drug Application), with the FDA's Office of Generic Drugs, which provides for the review and ultimate approval of a generic drug product. Once approved, an applicant may manufacture and market the generic drug product to provide a safe, effective, low cost alternative to the American public.

    "Abbreviated" because they are generally not required to include preclinical (animal) and clinical (human) data to establish safety and effectiveness. Instead, generic applicants must scientifically demonstrate that their product is bioequivalent. One way scientists demonstrate bioequivalence is to measure the time it takes the generic drug to reach the bloodstream in 24 to 36 healthy, volunteers.

    Timeline:

    1. February 4th, acquired Novalere FP.

    2. Currently, filing process for new ANDA.

    3. Fall, begin pre-approval activities.

    4. Winter of 2015/2016 anticipation of approval.

    5. This time next year, launch.

    So what is it exactly, that we found here and why do we like them so much, we signed them as a client?

    Innovus is an acquirer of non-prescription over the counter consumer care products. It's really like a publicly traded Shark Tank. While they don't have the audience Shark Tank does, nor the wherewithal to fund so many deals - what they do have is the ability to issue shares instead of writing checks, so everyone shares in the upside of the invention or product. Innovus, the Innovus shareholders and the inventor.

    They can acquire the product or acquire the manufacturer of the product, in exchange for stock. This makes for a large pool of potential acquisitions. As you can witness from nearly any episode of Shark Tank, hardly a day goes by where some enterprising inventor doesn't come up with a fantastic product - but can only take it to a certain level. Often that level is too small to take public where the funds needed (accounting, SEC related legal fees) are all better off spent on growing sales. And too small, to be acquired by big pharma, which often requires deeper proof of concept.

    Enter Innovus (OTCQB:INNV). To be brief, they find and acquire, they clean it up by outsourcing the best marketing and manufacturing partners, and then they enter into licensing and distribution agreements with experts in that field. There is a lot more Innovus than just Fluticare, we just think it is there most visible property for now and potentially their crown jewel.

    We should be out with a more in-depth report soon, which details their other acquisitions and delves further into Fluticare's potential.

    ==================================================

    2. HIV Vaccine Trial Launches in South Africa.

    "A safe and effective HIV vaccine is essential to reach a timely, sustained end to the HIV/AIDS pandemic," said Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. "The launch of HVTN 100 marks an important step forward in building upon the promising results of the RV144 trial to produce an HIV vaccine that could have a significant public health impact in southern Africa, where the HIV/AIDS pandemic is most pervasive."

    medicalxpress.com/news/2015-02-hiv-vacci...

    ==================================================

    3. Apricus Biosciences ($APRI) Provides Corporate Update and 2014 Year-End Financial Results.

    "In 2014, our overarching objective was to build Apricus into a development stage biopharmaceutical company with a diversified product pipeline with the potential to build meaningful long-term shareholder value," stated Richard Pascoe, Chief Executive Officer. "We successfully accomplished that objective with the in-licensing of fispemifene, a Phase 2 compound for the treatment of urological conditions in men and by initiating a Phase 2a clinical trial for RayVa(NYSE:TM), our product candidate for the circulatory disorder Raynaud's phenomenon. Moreover, we continued to make significant strides with our flagship product Vitaros(NYSE:R), our topical treatment for erectile dysfunction, highlighted by the successful commercial launch in 2014 by two of our European commercial partners.

    finance.yahoo.com/news/galena-biopharma-...

    ==================================================

    4. Galena Biopharma ($GALE) $1.38, Announces Pricing of Public Offering of $38 Million.

    PORTLAND, Ore., March 13, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care, today announced the pricing of an underwritten public offering of 24,358,974 units at a public offering price of $1.56 per unit, for total gross proceeds of $38.0 million. Each unit consists of one share of common stock and a warrant to purchase 0.5 of a share of common stock at an exercise price of $2.08 per share. The warrants are immediately exercisable and expire on the fifth anniversary of the date of issuance. The shares of common stock and warrants are immediately separable and will be issued separately.

    Raymond James & Associates, Inc. is acting as the sole book-running manager for the offering. Roth Capital Partners is acting as lead manager, and Maxim Group LLC, MLV & Co. LLC, and Noble Life Science Partners are acting as co-managers.

    finance.yahoo.com/news/galena-biopharma-...

    ==================================================

    5. What Is A Stem Cell ?

    In this video produced by ConnectEd California, Don Gibbons, from the California Institute for Regenerative Medicine, discusses the exciting field of stem cell research and the critical role that California is playing to help develop the field.

    www.youtube.com/watch?v=qBNene8Mybg

    ==================================================

    Innovus Pharma's Forward-Looking Safe Harbor: Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, receiving patent protection for any of its products, receiving approval or to be compliant with the requirements of any relevant regulatory authority relating to such products such as Zestra(R), to successfully commercialize such products in the Morocco and in other countries and regions, and to achieve its other development, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company. Institutional Analyst Inc has been compensated by Innovus for research services and ongoing coverage with three hundred thousand restricted and five-thousand dollars.

    Disclaimer: Important Distinction #1. First and foremost the Watch List is

    just that. A watch list. It is not a buy list. Meaning that there will be

    no buys or sales issued by the Reviews. If this was a buy

    list, you can rest assured that we would crank up our Public Relations arm

    into high gear, full speed ahead and damn the torpedoes to make everyone

    know just how brilliant we were when we issued the list. Interviews on

    CNBC, articles in Barron's and accolades in the Wall Street Journal--the

    only thing we love more than money is praise and fame--but it just isn't

    going to happen. What the Reviews are...is a "news

    aggregation service". With the advent of the Internet, everyone knows what

    that term means. What it means to us is the following: We will follow the

    progress of as many Internet related publicly traded stocks as humanly

    possible (The large, the small and the minuscule) and advise you of when

    they have reported news. As a subscriber to the Reviews,

    this means you will be able to broadly follow the entire industry right

    from a single e-mail. We will report who released news and point (with

    hyper links) to where the news can be found. We try to use Yahoo! Finance

    as extensively as possible so we don't send you all over cyberspace. We

    love Yahoo, you will too. Any decisions as to buy or sell however, are

    strictly up to you. Which leads to important distinction #2. How do we get

    paid? The Reviews are owned by a Public Relations firm

    (Institutional Analyst Inc.) that specializes in getting (or creating)

    coverage for publicly traded companies. As such, is important to note that

    anytime we say anything about a company, it is because the company is a

    client of our parent company, or because we would like them to be a client

    of our parent company. In a nutshell, you can throw out any thoughts of us

    being even a little bit impartial. It just ain't gonna happen. We love

    everyone. Final note is we that have over 20,000 subscribers so please

    excuse our dust. Institutional Analyst Inc. is an independent research and

    investor-relations consulting firm that publishes investment-research

    reports such as The Reviews on independently selected

    companies. While it is its intent to identify and research companies that

    it believes might prove to be profitable investments, The

    Review is not liable for any investment decisions by its readers. Neither

    The Reviews nor any report published by Institutional Analyst

    Inc., represent a solicitation to buy or sell the securities discussed

    within the report. It is strongly recommended that any purchase or sale

    decisions be discussed with a financial adviser or broker prior to

    completing any such purchase or sale decision. The information contained

    herein is provided as an information service only and is based upon

    sources deemed reliable, but not guaranteed by The Reviews.

    Past performance of previously featured companies does not guarantee the

    future success of any currently featured or mentioned company. The

    information contained herein is subject to change without notice, and The

    Reviews assumes no responsibility to update the information

    in this or any report published. Use of this or any report published by

    The Review may be subject to the applicable rules of

    certain self-regulatory organizations and the securities mentioned herein,

    which are traded Over The Counter, and may not be cleared for sale in

    certain states. Institutional Analyst Inc and/or its employees, officers,

    affiliates or members of their families may have long or short positions

    in any of the securities discussed in this or other reports published

    herein (and/or options or warrants relating thereto) and may purchase and

    or sell these securities, options or warrants from time to time in the

    open market or otherwise. Institutional Analyst Inc may derive

    compensation through research services and subscriptions and/or

    investor-relations consulting from the companies featured or mentioned in

    its reports. Write or call Institutional Analyst Inc for disclosure

    details as required by Rule 17b as it relates to individual issues.

    Institutional Analyst Inc., In no event shall The

    Reviews report be liable for direct, indirect, incidental or

    consequential damages resulting from the use of this information. The

    Reviews shall be indemnified and held harmless from any

    actions, claims, proceedings or liabilities with respect to the

    information herein. Institutional Analyst Inc is not a securities

    broker-dealer, investment advisor or a securities exchange and is not

    registered as such with the Securities and Exchange commission nor any

    state securities regulation authority. Readers of this e-mail newsletter

    should recognize that the Reviews are only providing a

    delivery service to electronically transmit information to potential

    investors. In this respect, the Reviews are no different than

    the provider of any other delivery service such as the United States Post

    Office or any other express delivery service. Accordingly, investors

    should be aware that the Reviews have not evaluated nor

    investigated any of the companies listed in this e-mail to determine their

    merit or the risk of investment in any such company. The Reviews do not

    endorse any company listed herein and the Reviews do not

    represent that the information contained in any offering documents states

    all material facts or does not omit a material fact necessary to make the

    statements therein not misleading. institutionalanalyst@gmail.com

    Tags: INNV, biotech
    Mar 23 2:39 AM | Link | Comment!
  • Initiating Coverage On Accurexa (ACXA) $2.50.

    ==================================================

    Stem Cell Stock Review, Monday, 03/23/2015.

    Los Angeles, CA 58 …69F Fair.

    Chicago, IL 31…45F Partly Cloudy.

    Delray Beach, FL 72…87 Partly Cloudy.

    Port Jefferson, NY 24…34F Fair. (198)

    To contact us send an email to: biotechstockreview@gmail.com

    ==================================================

    1. Initiating Coverage on Accurexa (OTCQB:ACXA) $2.50.

    2. Disclaimer.

    ==================================================

    1. Initiating Coverage on Accurexa (OTCQB:ACXA) $2.50.

    Accurexa Inc.

    201 Spear Street

    Suite 1100

    San Francisco, CA 94105

    Phone: 415-494-7850

    Website: www.accurexa.com

    "Drug delivery remains a major issue in brain tumor treatment…treatment failures can be expected on the basis of inadequate drug delivery alone, regardless of the effectiveness of the drug." Mir J. Ali MD, Northwestern University Medical School.

    "Failures expected, regardless of the effectiveness of the drug?"

    Them's some fighting words to the billion dollar brain cancer drug industry. But it is what it is and we've found the company that believes it has come up with a bigger and better trap (a device called BranchPoint) to deliver drugs to the brain - that could become the new standard for brain drug delivery - and make tens, if not hundreds of millions along the way if they are successful at doing it.

    This very exciting (some might say butt-kicking) medical device, which was developed at the UC San Francisco and initially funded with a $1.8 million grant from California's Institute for Regenerative Medicine (CIRM) and "rolled" into a publicly traded shell last summer - enabling investors (should they choose) to participate.

    Photo of BranchPoint: www.accurexa.com/technology.html

    CIRM, if you're unfamiliar is the nation's model of technology funding for "society's benefit" created by the kindness of the heavily taxed citizens of California, when they voted Proposition 71 though. The passage allocated $3 billion to establish the CIRM and created a biotech (stem cell) research hub rivaling Silicon Valley. So a shout out to California's taxpayers.

    This is an enticing, yet simple story to follow.

    Device Background:

    Failures expected: Way back in 2006, Dr Mir from Northwestern University Medical School took task to the recurring question "Is treatment failure of the brain's malignant tumors due to inadequate delivery or ineffective drugs?" Without going into details (see link to follow), he concluded that treatment failures are likely due to high interstitial fluid pressure. Because the infusion rates being used in the treatment of human brain tumors are low and the tumors are larger, treatment failures can be expected on the basis of inadequate drug delivery alone, regardless of the effectiveness of the drug.

    What this means to the stem cell industry, is if the delivery system fails - we risk total clinical trial failures - even if the biological reaction was valid. We cannot (should not) risk a $100 million clinical trail process to a $2.00 syringe. That's clearly unacceptable. End of that story. And beginning of Accurexa story.

    Dr. Mir's study:

    www.pubfacts.com/detail/16533759/Isolati...

    Failures averted: Fast forward to 2010 when Dr. Daniel Lim, a genius neurosurgeon and assistant professor at the University of California, San Francisco, who regularly uses a surgical device (a regular syringe with a steel needle developed in 1986) to deliver potentially life-changing treatments into patients' brains comes up with self described "crazy sounding idea" to improve the delivery of therapeutics (aka drugs) to the brain. It was after a using the standard device during a study of an experimental stem cell therapy at UCSF, Lim thought "...there must be a better way."

    In a San Francisco Business Journal article Lim stated, "...every time Parkinson's disease patients, for example, need cells transplanted into the brain, some must endure upwards of 10 injections because implanted cells don't spread through brain tissue. Every penetration, risks setting off bleeding in the brain."

    "Every time you put a needle into the brain, you run the risk of a hemorrhage and raise the risk of unwanted effects," says Ian Duncan, a neuroscientist at the University of Wisconsin­-Madison.

    "As experimental stem cell treatments progress, it only makes sense to use a tool built to deliver those cells rather than one designed nearly three decades ago. This could cut down on clinical trial failures at a critical time for scientists developing those treatments."

    So what does he do?

    Lim sketched his new device and turned it over to a group of UC Berkeley engineering students, who created a prototype. Then he won a $1.8 million grant in 2010 from the California Institute for Regenerative Medicine, the state's stem cell research funding organization, to push it through preclinical testing. Remember this "funding" point, because while our upcoming report will talk a lot about the deliver of stem cells to the brain (after-all that's where the until funding came from) we believe that the BranchPoint needle platform will be developed to deliver much more than just stem cells.

    Not unlike current delivery methods, Lim's instrument sits in a massive frame that is mounted on the head of a patient. A hole is drilled in the skull and doctors deliver cells or direct brain stimulation or other treatments to the brain.

    But instead of drilling multiple holes in the skull, the Accurexa device allows doctors to use a single entry point. They then can insert the hollowed, drug-bearing "plunger" - the diameter of hair - multiple times to multiple locations delivering treatments to as much as six locations in an hour.

    Unlike other needles used for cell therapies, Lim's device contains no ferromagnetic metals and so is compatible with MRI. The imaging enables researchers to monitor patients for signs of hemorrhaging and to combine cell therapy with other techniques, such as depositing electrodes for deep brain stimulation, an experimental therapy for Parkinson's disease.

    In fact, that's part of the beauty of the device: It could deliver cells, an electrode and gene therapy in a single session.

    "As a clinician, I tried to think it all the way through," Lim said. Ultimately, he said, the device could convince some drug developers to look anew at experimental treatments that had been developed as oral drugs but which may be hundreds of times more effective when delivered directly into the brain.

    "Up till now," Ivar Mendez, a neurosurgeon at Dalhousie University in Halifax, Canada says, "The way the injection has been done was with very primitive systems."

    Company Background:

    In our view, the Accurexa was essentially born, when they announced that they entered into their exclusive letter of intent (LOI) with the University of California, SF in regards to the exclusive global licensing of the BranchPoint device intended for the delivery of stem cells into the human brain. The LOI in July of 2014 became an actual license agreement in September of 2015.

    Prior to the UCSF agreement, Accurexa's primary mission was to usher through technology licensed from the University of Arkansas for Medical Sciences, focused on detecting metastatic cancer cells. That technology could take another three or four years to win FDA approval, whereas Accurexa plans the filing of its 510(k) marketing clearance application this summer or fall, before its "small business status" qualification status, which was granted by the FDA last week expires in September of this year.

    The agreement came after Lim was introduced to George Yu, the president and CEO of Accurexa. George whose background includes stints at Bain & Company, with small-cap hedge and venture capital funds and in investment banking at Lehman Brothers. Mr. Yu holds a Medical Doctor Degree from the University of Tuebingen, Germany, and a Master in Business Administration in Finance and Economics from Columbia Business School.

    An equally impressive resume is that of board member, Anchie Kuo. Dr. Kuo was a Managing Partner and co-Founder of Genaissance Capital Group, a top quartile healthcare focused hedge fund. He was also Managing Director of BankAmerica Ventures (Scale Ventures Partners), a venture group that managed approximately $1.2 billion of assets. He is a physician, venture capitalist and entrepreneur with over 25 years of experience in the healthcare industry, serving on the board of over 15 companies.

    In mid-January, Lim Development was awarded a two-year contract with the company for $200,000 which may be converted into stock at $0.20 a share or one million shares. So he has skin in the game to see this through to commercialization. If this works to dream status and the stock goes to $20 four or five years from now, he'll be worth $20 million, a fair reward for his genius - and something we can all benefit from, if it results in a safer more effective delivery of drugs to the brain.

    Accurexa submitted its application for Small Business qualification to the FDA in preparation of the filing of our 510(k) marketing clearance application last week.

    FDA Approves Accurexa's Small Business Qualification:

    finance.yahoo.com/news/fda-approves-accu...

    Great Technology Video (only nine minutes):

    www.youtube.com/watch?v=zTrZ5QRUIkA&t=22

    News Articles:

    Devices Aim to Deliver on Stem-Cell Therapies.

    www.nature.com/news/devices-aim-to-deliv...

    It's Not Brain Surgery - Well it is for Accurexa and Dr. Daniel Lim.

    www.bizjournals.com/sanfrancisco/blog/bi...

    University of California Breaks out of the Lab.

    www.bizjournals.com/sanfrancisco/feature...

    Cell Transplantation Into the Brain With Radially Branched Deployment

    www.nature.com/mt/journal/v23/n1/full/mt...

    "New To The Street" to Air First of a 6 Part Series Featuring Accurexa.

    This is the first installment of a six part series set to be aired nationwide to over 95 million homes on the History Channel.

    finance.yahoo.com/news/street-air-first-...

    Basic Financial Statistics.

    Shares outstanding, 5.7 million as of 9/30/2014. Market value @ $2.50 - $14.2 million.

    Cash & Equivalents, $748,000 (calling all investment bankers)

    Of course they're a client.

    ==================================================

    This release contains certain "forward-looking statements" relating to the business of the Company. All statements, other than statements of historical fact included herein are "forward-looking statements" including statements regarding: the ability of the Company to successfully develop and commercialize novel neurological therapies based on its BranchPoint device, ACX-31 and execute its business plan; the business strategy, plans, and objectives of the Company; and any other statements of non-historical information. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions and involve known and unknown risks and uncertainties. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume any duty to update these forward-looking statements. Institutional Analyst Inc., publisher of the Stem Cell Stock Review has been compensated with twenty-thousand shares for IR services including providing ongoing coverage of their progress and reporting in both the Biotech and Stem Cell Stock Review.

    Disclaimer: Important Distinction #1. First and foremost the Watch List is

    just that. A watch list. It is not a buy list. Meaning that there will be

    no buys or sales issued by the Reviews. If this was a buy

    list, you can rest assured that we would crank up our Public Relations arm

    into high gear, full speed ahead and damn the torpedoes to make everyone

    know just how brilliant we were when we issued the list. Interviews on

    CNBC, articles in Barron's and accolades in the Wall Street Journal--the

    only thing we love more than money is praise and fame--but it just isn't

    going to happen. What the Reviews are...is a "news

    aggregation service". With the advent of the Internet, everyone knows what

    that term means. What it means to us is the following: We will follow the

    progress of as many Internet related publicly traded stocks as humanly

    possible (The large, the small and the minuscule) and advise you of when

    they have reported news. As a subscriber to the Reviews,

    this means you will be able to broadly follow the entire industry right

    from a single e-mail. We will report who released news and point (with

    hyper links) to where the news can be found. We try to use Yahoo! Finance

    as extensively as possible so we don't send you all over cyberspace. We

    love Yahoo, you will too. Any decisions as to buy or sell however, are

    strictly up to you. Which leads to important distinction #2. How do we get

    paid? The Reviews are owned by a Public Relations firm

    (Institutional Analyst Inc.) that specializes in getting (or creating)

    coverage for publicly traded companies. As such, is important to note that

    anytime we say anything about a company, it is because the company is a

    client of our parent company, or because we would like them to be a client

    of our parent company. In a nutshell, you can throw out any thoughts of us

    being even a little bit impartial. It just ain't gonna happen. We love

    everyone. Final note is we that have over 20,000 subscribers so please

    excuse our dust. Institutional Analyst Inc. is an independent research and

    investor-relations consulting firm that publishes investment-research

    reports such as The Reviews on independently selected

    companies. While it is its intent to identify and research companies that

    it believes might prove to be profitable investments, The

    Review is not liable for any investment decisions by its readers. Neither

    The Reviews nor any report published by Institutional Analyst

    Inc., represent a solicitation to buy or sell the securities discussed

    within the report. It is strongly recommended that any purchase or sale

    decisions be discussed with a financial adviser or broker prior to

    completing any such purchase or sale decision. The information contained

    herein is provided as an information service only and is based upon

    sources deemed reliable, but not guaranteed by The Reviews.

    Past performance of previously featured companies does not guarantee the

    future success of any currently featured or mentioned company. The

    information contained herein is subject to change without notice, and The

    Reviews assumes no responsibility to update the information

    in this or any report published. Use of this or any report published by

    The Review may be subject to the applicable rules of

    certain self-regulatory organizations and the securities mentioned herein,

    which are traded Over The Counter, and may not be cleared for sale in

    certain states. Institutional Analyst Inc and/or its employees, officers,

    affiliates or members of their families may have long or short positions

    in any of the securities discussed in this or other reports published

    herein (and/or options or warrants relating thereto) and may purchase and

    or sell these securities, options or warrants from time to time in the

    open market or otherwise. Institutional Analyst Inc may derive

    compensation through research services and subscriptions and/or

    investor-relations consulting from the companies featured or mentioned in

    its reports. Write or call Institutional Analyst Inc for disclosure

    details as required by Rule 17b as it relates to individual issues.

    Institutional Analyst Inc., In no event shall The

    Reviews report be liable for direct, indirect, incidental or

    consequential damages resulting from the use of this information. The

    Reviews shall be indemnified and held harmless from any

    actions, claims, proceedings or liabilities with respect to the

    information herein. Institutional Analyst Inc is not a securities

    broker-dealer, investment advisor or a securities exchange and is not

    registered as such with the Securities and Exchange commission nor any

    state securities regulation authority. Readers of this e-mail newsletter

    should recognize that the Reviews are only providing a

    delivery service to electronically transmit information to potential

    investors. In this respect, the Reviews are no different than

    the provider of any other delivery service such as the United States Post

    Office or any other express delivery service. Accordingly, investors

    should be aware that the Reviews have not evaluated nor

    investigated any of the companies listed in this e-mail to determine their

    merit or the risk of investment in any such company. The Reviews do not

    endorse any company listed herein and the Reviews do not

    represent that the information contained in any offering documents states

    all material facts or does not omit a material fact necessary to make the

    statements therein not misleading. institutionalanalyst@gmail.com

    Mar 23 2:26 AM | Link | Comment!
  • Top 20 Stem Cell Stocks For 2015.

    Chicago IL / Research Report Wire / February 27th, 2015 / Institutional Analyst Inc.(IA) announced today released the Top 20 Stem Cell Watch List for 2015 and launching the Stem Cell Stock Review website as a companion site to the Biotech Stock Review which was launched in 2002.

    Stem Cell Stock Review: http://www.stemcellstockreview.com/

    Stem Cell Magazine: http://goo.gl/OHBnWu

    Biotech Exec TV: http://www.biotechexectv.com/

    IA is an independent investment research firm founded in 1998, with the launch of the "Internet Stock Review" and additionally provides coverage for companies in a number of distinct industries including; Beverages, Biotech, Internet, Patent Monetization, Alternative Energy, Entertainment, Restaurants, Special Situations and Private Equity.

    Extensive stem cell research is being done relating to the treatment of cancer, wound healing, Parkinson's disease, and multiple sclerosis. Due to controversy about embryonic stem cells, many alternative sources for deriving stem cells are being studied, including Autologous Adipose cells, meaning derived from your own fat tissue. Prices in our database range from as low as $0.06 for International Stem Cell ($ISCO), to as high at $98 for BlueBird Bio ($BLUE). Market capitalizations excluding convertible debt, range from under $10 million to as large as $3 billion. Each possess compelling stem cell related technology. The Stem Stock Review was created as a starting point to help those investors searching for lower priced and smaller capitalization companies and is not a recommended list.

    Top 20 Stem Cell Stocks for 2015.

    *America Cryostem (OTCPK:CRYO) $0.29

    Accurexa Inc. (OTCQB:ACXA) $2.95

    Asterias Biotherapeutics, Inc. (OTC:AST) $3.96

    Athersys, Inc. (NASDAQ:ATHX) $2.59

    Brainstorm Cell Therapeutics Inc. (OTCQB:BCLI) $3.81

    BluebirdBio, Inc. (NASDAQ:BLUE) $93.80

    BioTime, Inc. (NYSEMKT:BTX) $4.05

    Cesca Therapeutics Inc. (NASDAQ:KOOL) $0.88

    *Cellular Biomedicine Group Inc. (OTCQB:CBMG) $28.46

    Cellular Dynamics International, Inc. (NASDAQ:ICEL) $5.11

    Cryo-Cell International, Inc. (OTCPK:CCEL) $2.50

    Cynata Therapeutics Limited (CYP.AX) $0.94

    Cytori Therapeutics, Inc. (NASDAQ:CYTX) $0.73

    Fate Therapeutics, Inc. (NASDAQ:FATE) $4.87

    International Stem Cell Corporation (OTCQB:ISCO) $0.06

    Kadimastem (KDST.TA) $219

    Mesoblast Limited (MSB.AX) $4.50

    Neuralstem, Inc. (NYSEMKT:CUR) $3.60

    Pluristem Therapeutics, Inc. (NASDAQ:PSTI) $3.07

    RepliCel Life Sciences Inc. (OTCQB:REPCF) $0.32

    Vitro Diagnostics, Inc. (OTCPK:VODG) $0.19

    *American Cryostem ($CRYO) $0.29

    American Cryostem operates a state-of-the-art, FDA-registered, clinical laboratory dedicated to processing, bio-banking and manufacturing of cellular applications using autologous adipose (fat) tissue and adipose derived stem cells. Through its scientific efforts, the Company has built a strong, strategic portfolio of intellectual property, patent applications, and proprietary operating procedural processes that form its standardized cellular platform. Our growth strategy is centered on fully capitalizing on the scientific breakthroughs that have been rapidly shaping the Regenerative and Personalized Medicine industries; and provide these industries with a standardized cell processing platform to enhance the delivery of healthcare through cellular-based therapies and applications which address burn and wound healing, joint repair, disease treatment and management, and personalized health care.

    http://www.americancryostem.com/

    Accurexa Inc. ($ACXA) $2.95

    The Company is focused on developing and commercializing novel neurological therapies based on its proprietary BranchPoint technology delivering therapeutics directly into specific regions of the brain. The BranchPoint device delivers therapeutics through the radial deployment of a flexible delivery catheter to large and anatomically complex brain targets through a single initial brain penetration. Clinicians can "tailor" therapeutic delivery to individual patient anatomy and specific disease targets, which may enhance the efficacy of therapies. The BranchPoint device also gives physicians more precise control of the volume of therapeutics delivered and ensures that therapeutics delivered into the brain stay in the brain, avoiding the problem of reflux out to the brain surface. This modern and "easy to use" technology allows "real-time" monitoring of therapeutic delivery under interventional MRI guidance (iMRI), which can improve the accuracy of therapeutic delivery, reduce the risk of complications, and increase patient safety. The BranchPoint device was developed at the University of California, San Francisco (UCSF) with $1.8 million in funding from the California Institute for Regenerative Medicine (CIRM). It is based on a neurosurgical delivery platform that the Company has exclusively licensed from UCSF. It can enable new approaches to neurological therapy and be modified for the delivery of a broad range of novel therapeutics, such as stem cells to treat neurodegenerative diseases, chemotherapeutics to brain tumors and gene therapy vectors.

    http://www.accurexa.com/

    Asterias Biotherapeutics, Inc. ($AST) $3.96

    Asterias Biotherapeutics, Inc., a biotechnology company, focuses on the development of therapeutic products to treat neurology, oncology, cardiology, metabolic diseases, ophthalmology, orthopedics, and blood and vascular diseases. The company focuses on developing pluripotent stem-cell based therapies in neurology and oncology, including AST-OPC1 neural cells to treat spinal cord injury, multiple sclerosis, and stroke; and AST-VAC2, a pluripotent stem cell-derived cancer vaccine. It also has additional product candidates that it intends to develop from various cell types comprising AST-VAC1 for the treatment of cancer; CHND1 for the treatment of osteoarthritis; and CM1 for the treatment of heart failure and myocardial infarction. The company was formerly known as BioTime Acquisition Corporation and changed its name to Asterias Biotherapeutics, Inc. in March 2013. Asterias Biotherapeutics, Inc. was founded in 2012 and is based in Menlo Park, California. Asterias Biotherapeutics, Inc. is a subsidiary of BioTime, Inc.

    http://asteriasbiotherapeutics.com/

    Athersys, Inc. ($ATHX) $2.59

    Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. The company’s lead platform product, MultiStem cell therapy, an allogeneic stem cell product, which has Phase I clinical trials for the patients that have suffered an acute myocardial infarction, and leukemia or other blood-borne cancers; and is ongoing Phase II clinical trials for the patients suffering from inflammatory bowel disease (IBD) and ischemic stroke. Its clinical development programs are focused on treating inflammatory and immune disorders, neurological conditions, cardiovascular disease, and other conditions. The company is also involved in identifying and developing small pharmaceuticals to treat obesity; related metabolic conditions, such as diabetes; and neurological indications, including schizophrenia. It has collaboration agreement with Pfizer Inc. to develop and commercialize MultiStem to treat IBD; and RTI Biologics, Inc. to develop and commercialize biologic implants for orthopedic applications in the bone graft substitutes market.

    http://www.athersys.com/

    Brainstorm Cell Therapeutics Inc. ($BCLI) $3.81

    Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders, such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis. It holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. The company’s NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor and brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons. It is developing NurOwn, an autologous adult stem cell product for the treatment of ALS. Brainstorm Cell Therapeutics Inc. also has agreements with Hadasit Medical Research Services and Development Ltd. to conduct its ALS clinical trials at the Hadassah Medical Center.

    http://www.brainstorm-cell.com/

    BluebirdBio, Inc. ($BLUE) $93.80

    With its lentiviral-based gene therapy and gene editing capabilities, bluebird bio has built an integrated product platform with broad potential application to severe genetic diseases and T cell-based immunotherapy. bluebird bio's clinical programs include Lenti-D™, currently in a Phase 2/3 study, called the Starbeam Study, for the treatment of childhood cerebral adrenoleukodystrophy, and LentiGlobin®, currently in three clinical studies: a global Phase 1/2 study, called the Northstar Study, for the treatment of beta-thalassemia major; a single-center Phase 1/2 study in France (HGB-205) for the treatment of beta-thalassemia major or severe sickle cell disease; and a separate U.S. Phase 1 study for the treatment of sickle cell disease (HGB-206). bluebird bio also has a preclinical CAR T cancer immunotherapy program in collaboration with Celgene Corporation, as well as discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies.

    http://www.bluebirdbio.com/

    BioTime, Inc. ($BTX) $4.05

    BioTime is a biotechnology company engaged in research and product development in the field of regenerative medicine. Regenerative medicine refers to therapies based on stem cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. BioTime's focus is on pluripotent stem cell technology based on human embryonic stem ("hES") cells and induced pluripotent stem ("iPS") cells. hES and iPS cells provide a means of manufacturing every cell type in the human body and therefore show considerable promise for the development of a number of new therapeutic products. BioTime's therapeutic and research products include a wide array of proprietary PureStem® progenitors, HyStem® hydrogels, culture media, and differentiation kits. Renevia™ (a HyStem® product), is now in a pivotal trial in Europe as a biocompatible, implantable hyaluronan and collagen-based matrix for cell delivery in the treatment of HIV-related lipoatrophy. In addition, BioTime has developed Hextend®, a blood plasma volume expander for use in surgery, emergency trauma treatment and other applications. Hextend® is manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ HealthCare Corporation, under exclusive licensing agreements.

    http://www.biotimeinc.com/

    Cellular Biomedicine Group Inc. ($CBMG) $28.46

    Cellular Biomedicine Group, Inc., a biomedicine company, develops treatments for cancerous and degenerative diseases in Greater China. The company operates through two segments, Biomedicine and Consulting. It focuses on developing and marketing cell-based therapies to treat serious chronic and degenerative diseases, such as cancer, osteoarthritis, tissue damage, spinal muscular atrophy, various inflammatory diseases, and joint degeneration and metabolic diseases. The company develops treatments utilizing proprietary cell technologies comprising tumor cell specific dendritic cells for the treatment of a range of cancers; human adipose-derived mesenchymal progenitor cells for the treatment of joint disease; human umbilical cord-derived mesenchymal progenitor cells; human embryo-derived motor neuron progenitor precursor cells; and human embryo-derived neuronal progenitor precursor cells for the treatment of central nervous system diseases.

    http://cellbiomedgroup.com/

    Cellular Dynamics International, Inc. ($ICEL) $5.11

    Cellular Dynamics International, Inc. (NYSE:CDI) is a leading developer and manufacturer of fully functioning human cells in industrial quantities to precise specifications. CDI's proprietary iCell Operating System (iCell O/S) includes true human cells in multiple cell types (iCell products), human induced pluripotent stem cells (iPSCs) and custom iPSCs and iCell products (MyCell Products). CDI's iCell O/S products provide standardized, easy-to-use, cost-effective access to the human cell, the smallest fully functioning operating unit of human biology. Customers use our iCell O/S products, among other purposes, for drug discovery and screening; to test the safety and efficacy of their small molecule and biologic drug candidates; for stem cell banking; and in the research and development of cellular therapeutics. CDI was founded in 2004 by Dr. James Thomson, a pioneer in human pluripotent stem cell research at the University of Wisconsin-Madison.

    http://www.cellulardynamics.com/

    Cryo-Cell International, Inc. ($CCEL) $2.50

    Cryo-Cell International, Inc. is engaged in cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. The company offers advanced cord tissue service, which stores a section of the umbilical cord tissue, which is a source of mesenchymal stem cells that are used in regenerative medicine research targeting potential therapies for a range of conditions, including heart disease, stroke, multiple sclerosis, and diabetes; and reproductive tissue storage service for cryopreserved embryos, oocytes, and sperm that offers reproductive tissue services, including short and longer-term cryogenic storage, inter-facility transportation coordination, and special quarantined cryogenic storage for infectious disease positive specimens. It stores approximately 300,000 cord blood and cord tissue specimens worldwide. The company markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals.

    http://www.cryo-cell.com/

    Cynata Therapeutics Limited ($CYP.AX) $0.94

    Cynata Therapeutics Ltd is an Australian stem cell and regenerative medicine company developing and commercialising a novel method for producing scalable quantities of mesenchymal stem cells for therapeutic application. The platform technology, Cymerus™, originates from the University of Wisconsin-Madison, a facility that is widely recognised as a world leader in stem cell research. Cynata's proprietary Cymerus™ technology seeks to address a critical shortcoming in existing production methods of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. Cymerus™ achieves this by producing a particular type of MSC precursor, called a mesenchymoangioblast (NYSE:MCA). The Cymerus™ MCA technology provides a source of MSCs that are independent of donor limitations and provide a potential "off-the-shelf" stem cell platform for therapeutic product use, with a pharmaceutical business model and economies of scale. The Cymerus™ technology has great potential to create a new standard globally in stem cell therapeutics, with a novel manufacturing technology and an important competitive position.

    http://cynata.com/

    Cytori Therapeutics, Inc. ($CYTX) $0.73

    Cytori Therapeutics is a late stage cell therapy company developing autologous cell therapies from adipose tissue to treat a variety of medical conditions. Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy™ acts principally by improving blood flow, modulating the immune system, and facilitating wound repair. As a result, Cytori Cell Therapy™ may provide benefits across multiple disease states and can be made available to the physician and patient at the point-of-care through Cytori's proprietary technologies and products.

    http://www.cytori.com/Home.aspx

    Fate Therapeutics, Inc. ($FATE) $4.87

    Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops pharmacologic modulators of adult stem cells to treat orphan diseases. Its hematopoietic stem cell (NYSE:HSC) modulation platform focuses on the ex vivo pharmacologic optimization of hematopoietic stem cells, which are adult stem cells that regenerate various types of blood cells throughout a person’s lifespan; and satellite cell modulation platform focuses on the in vivo pharmacologic activation of satellite stem cells that are adult stem cells that regenerate muscle throughout a person’s lifespan. The company’s lead product candidate includes ProHema, a pharmacologically-modulated HSC therapeutic derived from umbilical cord blood that is in Phase II clinical development for hematologic malignancies. It is developing pharmacologically optimized HSC therapeutics for the treatment of lysosomal storage disorders within the central nervous system; and Wnt7a Analogs that is in preclinical studies for regeneration in muscular dystrophies.

    http://fatetherapeutics.com/

    International Stem Cell Corporation ($ISCO) $0.06

    International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial backgrounds, with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (lifelineskincare.com).

    http://www.internationalstemcell.com/

    Kadimastem ($KDST.TA) $219

    Kadimastem uses human stem cells that are differentiated to create medical solutions for diabetes and degenerative diseases of the nervous system and for drug screening. The company's technological platform enables the differentiation of stem cells into a range of functional human cells, including neuron-supporting cells in the brain as well as pancreatic cells that secrete insulin - beta cells. Kadimastem relies on technology that was initially invented at the Weizmann Institute in Prof. Michel Revel's laboratory, and which is now being further developed and advanced in the company's labs at the Weizmann Science Park. Kadimastem is developing two types of medical applications: A. Regenerative medicine, the purpose of which is to repair and replace tissues and organs damaged by disease using healthy cells grown in laboratory conditions, for example, transplantation of insulin-secreting pancreas cells to treat insulin-dependent diabetes, or transplantation of healthy brain-supporting cells to improve survival of nerve cells and treat ALS; B. Drug screening platforms which use functional human cells and tissues to discover new medicinal drugs.

    http://www.kadimastem.com/

    Mesoblast Limited ($MSB.AX) $4.50

    Mesoblast Limited is a global leader in regenerative medicine. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells (MLCs), to establish a broad portfolio of late stage product candidates. Mesoblast's allogeneic or 'off-the-shelf' cell product candidates target significantly advanced stages of diseases where there are highly unmet medical needs, including cardiovascular conditions, orthopedic disorders, immunologic/inflammatory disorders and oncology/hematology conditions. The lead therapeutic product candidates under investigation include MPC-150-IM for chronic congestive heart failure, in partnership with Teva Pharmaceutical Industries Ltd., MPC-06-ID for chronic discogenic low back pain, MSC-100-IV for acute graft versus host disease, and MPC-300-IV for biologic refractory rheumatoid arthritis and diabetic nephropathy.

    http://www.mesoblast.com/

    Neuralstem, Inc. ($CUR) $3.60

    Neuralstem is a dual platform regenerative medicine company. The company's technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (NYSE:CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders.

    Neuralstem's small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company's lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (NYSEARCA:MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem's first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig's disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic stroke.

    http://www.neuralstem.com/

    Pluristem Therapeutics, Inc. (PSTI) $3.07

    Pluristem Therapeutics Inc. is a leading developer of placenta-based cell therapy products. The Company's patented PLX (PLacental eXpanded) cells release a cocktail of therapeutic proteins in response to inflammation, ischemia, hematological disorders, and radiation damage. PLX cells are grown using the Company's proprietary three-dimensional expansion technology and are an "off-the-shelf" product that requires no tissue matching prior to administration. Pluristem has a strong intellectual property position, Company-owned, GMP-certified manufacturing and research facilities, strategic relationships with major research institutions, and a seasoned management team.

    http://pluristem.com/

    RepliCel Life Sciences Inc. (OTCQB:REPCF) $0.32

    RepliCel is a regenerative medicine company focused on developing autologous cell therapies that address conditions caused by a deficit of healthy cells required for normal healing and function. The company's RCT-01, RCS-01, and RCH-01 cell therapies are designed to treat chronic tendinosis, damaged or aging skin, and pattern baldness. Shiseido Company, Limited has an exclusive license for RCH-01 in certain Asian countries including Japan , China and South Korea . All product candidates are based on RepliCel's innovative technology utilizing cell populations isolated from a patient's own healthy hair follicles. The company is also developing a propriety injection device optimized for the administration of its products and licensable for use with other dermatology applications. The company's product pipeline is comprised of multiple clinical trials anticipated to launch in 2015 in addition to Shiseido's own clinical trial of RCH-01 and the device in late prototype development

    http://www.replicel.com/

    Vitro Diagnostics, Inc. (OTCPK:VODG) $0.19

    Vitro Diagnostics, Inc. owns US patents for production of FSH, immortalization of pituitary cells, and a cell line that produces beta islets for use in treatment of diabetes. In 2011, Vitro Biopharma out-licensed its intellectual property related to treatment of infertility to Dr. James Posillico, a renowned expert in Assisted Reproductive Technologies. Vitro Biopharma also owns a pending patent for methods and materials related to treatment of neurological conditions by activation of neural stem cells. Vitro Biopharma's mission is "Harnessing the Power of Cells(NYSE:TM)" for the advancement of regenerative medicine to its full potential. Vitro Biopharma operates within a modern biotechnology manufacturing, R&D and corporate facility in Golden, Colorado. Vitro Biopharma manufactures and sells "Tools for Stem Cell and Drug Development(TM)," including human mesenchymal stem cells and derivatives, the MSC-Gro(TM) Brand of optimized media for MSC self-renewal and lineage-specific differentiation. In addition to our FSH patent licensee, Vitro Biopharma maintains several strategic partnerships including an alliance with Neuromics, Inc. (neuromics.com). Neuromics, Inc. is a primary distributor of Vitro Biopharma products and a well established manufacturer and distributor of a large variety of life science research products especially focused on cell-based assay systems. Also, Vitro Biopharma's CEO is a consultant on an NSF grant at the City College of New York to advise Dr. Lane Gilcrest, Professor of Materials Science and Engineering, and his colleagues regarding the development of novel extracellular materials for use in self-renewal and differentiation of mesenchymal stem cells.

    http://vitrobiopharma.com/

    About Institutional Analyst

    Institutional Analyst Inc. (IA), an independent investment research and investor relations firm. IA is a leading publisher of news, perspective and market intelligence reports on the equity markets. Working with publicly traded corporations, the firm seeks out small-cap companies which have products and/or services and management which can best be described as "best of breed." To best align itself with shareholders, IA typically seeks to have 90% of its retainer, represented by an equity stake in its client companies. When compensated for providing research reports or coverage, IA will provide all details on its website or report in a manner fully compliant with current regulatory guidelines. While we are not an impartial organization, we endeavor our best to initiate research coverage on companies which believe may perform well after initiating coverage.

    Senior executives at publicly traded companies seeking to expand their awareness amongst investors who have an interest in stem cell and biomedical stocks, or to be interviewed on Biotech Exec TV may contact us at the number listed below, initial contact by email is preferred.

    Founded in 1995 and based in Chicago, the heart of the trading industry, Institutional Analyst has offices in Beverly Hills, CA, Chicago IL, Delray Beach, FL and Port Jefferson, NY.

    About The Stem Cell Stock Review

    The Stem Stock Review website provides individual news feeds for each company on the Watch List, enabling investors to easily follow the entire group with a single visit. Each Friday we issue a weekly "head-line" wrap up of stem cell industry news via our free newsletter. Also included are links to third party industry expert websites and leading news sources such as the Life Sciences Report, Edison Research, Futurity, the Timmerman Report, Fierce Biotech, BioMed Reports, Science Daily and research reports from a broad spectrum of Wall Street sources.

    Stem Cell Stock Review Website: http://www.stemcellstockreview.com/home.html

    The Stem Cell Stock Review additionally has a Flipboard powered magazine which archives a collection of stem cell industry related articles from over 100 sources and can be found here:

    Stem Cell Stock Review Magazine: http://goo.gl/OHBnWu

    The Stem Cell Stock Review additionally has an online Internet TV channel called Biotech Exec TV, which hosts interviews with industry and Wall Street experts.

    Biotech Exec TV: http://www.biotechexectv.com/

    Contact:

    Roland Rick Perry

    Managing Director, Institutional Analyst Inc.

    email: biotechstockreview@gmail.com (preferred contact method)

    Phone: 310-594-8062

    Seeking Alpha: seekingalpha.com/author/roland-rick-perry

    Stock Twits: stocktwits.com/RolandRickPerry

    Harvest Exchange: www.hvst.com/14283-roland-rick-perry

    SEC guide for Microcap stocks: www.sec.gov/investor/pubs/microcapstock.htm

    All prices above as of 2/24/2015

    *American CryoStem was added to Watch List at $0.21 in February of 2015. Cellular Biosciences was added to to the Watch List in January of 2015 at $16.59.

    Tags: stem cell
    Mar 05 8:15 PM | Link | Comment!
Full index of posts »
Latest Followers

StockTalks

More »

Latest Comments


Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.